Production (Stage)
Akero Therapeutics, Inc.
AKRO
$46.36
-$2.61-5.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -50.30% | -66.09% | -98.29% | -76.75% | -60.30% |
| Total Depreciation and Amortization | -10.53% | -37.93% | -86.49% | -79.07% | -55.81% |
| Total Amortization of Deferred Charges | -15.56% | -22.68% | -27.14% | -31.48% | 162.17% |
| Total Other Non-Cash Items | 47.03% | 49.66% | 20.15% | -33.98% | -43.96% |
| Change in Net Operating Assets | -250.16% | 144.95% | 148.02% | 53.84% | 233.65% |
| Cash from Operations | -68.49% | -58.29% | -73.13% | -96.53% | -65.34% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -253.80% | 51.39% | 67.09% | -48.19% | -165.80% |
| Cash from Investing | -254.34% | 50.94% | 66.79% | -48.67% | -165.80% |
| Total Debt Issued | -100.00% | -33.33% | -33.33% | -33.33% | -60.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -31.65% | 28.78% | 1.68% | -37.34% | 167.01% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -53.41% | -8.76% | 94.25% | 94.82% | 95.00% |
| Cash from Financing | -32.71% | 26.19% | 4.17% | -35.72% | 160.52% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -219.70% | 776.48% | 144.49% | -150.24% | 240.67% |